1. Introduction {#sec1-cancers-12-01592}
===============

Esophageal cancer patients often present with an advanced disease stage, encompassing metastatic lymph nodes or distant metastases. The presence and number of lymph node metastases are among the most important prognostic factors in esophageal carcinoma and are independent predictors for long-term survival \[[@B1-cancers-12-01592],[@B2-cancers-12-01592],[@B3-cancers-12-01592],[@B4-cancers-12-01592],[@B5-cancers-12-01592],[@B6-cancers-12-01592]\].

The location of metastatic lymph nodes depends on tumor histology, primary tumor location, T-stage and neo-adjuvant therapy \[[@B7-cancers-12-01592]\]. The vessels in the dense lymphatic network surrounding the esophagus are complexly aligned and they contribute to a multidirectional spread of lymph node metastases in the abdomen, the mediastinum, and the neck \[[@B8-cancers-12-01592],[@B9-cancers-12-01592]\]. Additionally, 'skip metastasis', skipping the first and directly metastasizing into the second or third lymph node echelons, are frequently seen in both esophageal adenocarcinoma and squamous cell carcinoma \[[@B10-cancers-12-01592],[@B11-cancers-12-01592]\]. This contributes to the presence of lymph node metastases at unexpected distant sites, which makes standardization of the extent of the radiation field and lymphadenectomy in the treatment of esophageal cancer difficult. Not surprisingly, the optimal extent of the lymphadenectomy in esophagectomy has been subject of a global debate over the past decades \[[@B12-cancers-12-01592],[@B13-cancers-12-01592]\]. In addition, several classification systems exist, contributing to the heterogeneity in the reporting of studies and clinical practice \[[@B14-cancers-12-01592],[@B15-cancers-12-01592]\].

An extensive lymphadenectomy may result in more post-operative complications, while an insufficient lymphadenectomy carries the risk of understaging and undertreating patients, which may reduce long-term survival \[[@B16-cancers-12-01592]\]. In Western countries, a two-field lymphadenectomy is preferred for distal esophageal adenocarcinomas. Especially in the upper mediastinum, the extent varies considerably among surgeons, centers, and countries \[[@B17-cancers-12-01592]\]. In Asia, where predominantly squamous cell carcinoma is seen, an extensive three-field lymphadenectomy is common practice \[[@B12-cancers-12-01592]\].

Current studies on metastatic lymphatic mapping in esophageal cancer suggest possible dissemination patterns but do not come forward with sufficient evidence to determine the optimal extent of the radiation field and lymphadenectomy. The lack of homogeneity concerning the classification of lymph node stations makes the interpretation of studies difficult and data hard to compare. In other types of cancer, such as pancreatic, breast, and in colon cancer, the standardization of lymphadenectomy has already been established and it has improved oncologic outcome in the long term \[[@B18-cancers-12-01592],[@B19-cancers-12-01592],[@B20-cancers-12-01592]\].

The objective of this review is to identify the locoregional distribution of lymph node metastases in esophageal cancer patients in potentially curable patients, stratified for histology, tumor location, and T-stage. An outline on metastatic lymphatic distribution patterns may contribute to a uniform worldwide staging system and to the standardization of the extent of the radiation field and lymphadenectomy in esophageal carcinoma.

2. Methods {#sec2-cancers-12-01592}
==========

A review protocol was developed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement ([www.prisma-statement.org](www.prisma-statement.org)) and was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42018102804). PubMed and Embase were searched on 22 July 2019. The following terms were used (including synonyms and closely related words) as index terms or free-text words: 'esophageal cancer (including junctional carcinomas)' and 'lymph node metastasis' and 'lymphadenectomy'. The full search strategies for PubMed and Embase.com can be found in [Appendix A](#app1-cancers-12-01592){ref-type="app"}. Duplicate articles were excluded.

Articles were screened by two independent researchers (EH, SSG) in two stages: screening of titles and abstracts followed by the retrieval and screening of full-text articles. Inclusion criteria were as follows: studies describing a complete 2- or 3-field lymphadenectomy by transthoracic esophagectomy, the prevalence of patients with lymph node metastases per lymph node station is given or can be calculated, data is separately reported for adenocarcinoma and/or squamous cell carcinoma and tumor location. We excluded studies describing surgery following neo-adjuvant therapy (because the distribution may be different after neo-adjuvant chemo(radio)therapy), imaging studies, case reports, conference abstracts and reviews, and papers in another language than English or Dutch.

2.1. Data Extraction {#sec2dot1-cancers-12-01592}
--------------------

The primary endpoint is the metastatic rate of lymph node metastases in esophageal carcinoma per lymph node station or region. When available, the following variables were extracted from the included studies: year of publication; country; study design; inclusion period; lymph node classification system used (JES, Japan Esophageal Society; AJCC, American Joint Committee on Cancer; other; none); description of how detailed lymph node regions or stations are described and reported; number of patients; patient characteristics (gender, age); tumor histology; tumor location (upper thoracic esophagus, middle thoracic esophagus, lower thoracic esophagus or gastroesophageal junction (GEJ)); c/pT-stage; c/pN-stage; type of surgical approach; lymphadenectomy (complete 2- or 3- field); use of immunohistochemistry staining; prevalence of lymph node metastases per lymph node station; number of patients with lymph node metastases; overall percentage of positive lymph nodes; number of patients per lymph node location with resected nodes and positive nodes in that station or region. Methodological quality was assessed using the Methodological Index for Non-Randomized Studies (MINORS) checklist \[[@B21-cancers-12-01592]\].

2.2. Statistical Analysis {#sec2dot2-cancers-12-01592}
-------------------------

Descriptive statistics summarized the characteristics of included studies, patient characteristics, and the outcomes of each included study. Since not all studies used the same classification or definition for lymph node stations, and some studies only reported lymph node data for different regions instead of stations, we combined the two mostly used systems (JES and AJCC) and grouped lymph node stations into five regions: cervical, upper mediastinal, middle mediastinal, lower mediastinal, and abdominal ([Table 1](#cancers-12-01592-t001){ref-type="table"}). Studies with a reported number of patients with metastatic lymph nodes per station were pooled separately from the studies only describing data per region. The prevalence of patients with lymph node metastases per station or region were calculated by summarizing all the patients with lymph node metastases per lymph node station or region and dividing them by the sum of all patients who had a lymph node dissection in this station or region. Results were stratified for tumor histology and primary tumor location. Finally, studies describing the lymphatic distribution pattern according to the pT-stage were pooled and described separately.

3. Results {#sec3-cancers-12-01592}
==========

Details of the literature search and study selection are shown in [Figure 1](#cancers-12-01592-f001){ref-type="fig"}. Fourteen studies met the inclusion criteria and were included in this review \[[@B7-cancers-12-01592],[@B22-cancers-12-01592],[@B23-cancers-12-01592],[@B24-cancers-12-01592],[@B25-cancers-12-01592],[@B26-cancers-12-01592],[@B27-cancers-12-01592],[@B28-cancers-12-01592],[@B29-cancers-12-01592],[@B30-cancers-12-01592],[@B31-cancers-12-01592],[@B32-cancers-12-01592],[@B33-cancers-12-01592],[@B34-cancers-12-01592]\]. Characteristics of the included studies are presented in [Table 2](#cancers-12-01592-t002){ref-type="table"}. A total of 8952 patients were evaluated, including 409 (5%) with an adenocarcinoma and 8543 (95%) with a squamous cell carcinoma. Among all patients with a squamous cell carcinoma, 726 (9%) patients had a tumor located in the upper thoracic esophagus, 5130 (60%) patients had a tumor in the middle thoracic esophagus and 2687 (31%) had a tumor in the lower thoracic esophagus. None of these studies described patients with a cervical or GEJ squamous cell carcinoma. For adenocarcinoma, 32 (8%) tumors were located in the distal esophagus and 377 (92%) were located at the GEJ. The c/pT stage varied among studies, but most of the patients had a c/pT3 tumor. Details of the study populations can be found in [Table 2](#cancers-12-01592-t002){ref-type="table"} and [Table 3](#cancers-12-01592-t003){ref-type="table"}.

3.1. Reporting Standard {#sec3dot1-cancers-12-01592}
-----------------------

Standard reported lymphadenectomy differed among studies. In 1 study, patients underwent a 2-field lymphadenectomy, in 9 studies, patients underwent a 3-field lymphadenectomy, and in 4 studies, both procedures were included, resulting in a different nodal yield per study. In addition, the definition of anatomical locations of lymph node stations differed amongst studies; 1 study used AJCC, 5 used JES, and 8 did not use a standard classification system. Moreover, 6 studies described the prevalence of lymph node metastases per lymph node station, 5 only described the prevalence of lymph node metastases per region, and 3 reported a combination of both. The reported regions and stations also varied among studies ([Table 2](#cancers-12-01592-t002){ref-type="table"}). Some studies described for some stations both sides together, and other studies separated left and right. One study combined tumor locations when reporting the number of patients per lymph node station and could therefore not be pooled with the others studies \[[@B7-cancers-12-01592]\].

3.2. Distribution Pattern for Esophageal Squamous Cell Carcinoma {#sec3dot2-cancers-12-01592}
----------------------------------------------------------------

Eleven studies \[[@B7-cancers-12-01592],[@B22-cancers-12-01592],[@B24-cancers-12-01592],[@B26-cancers-12-01592],[@B27-cancers-12-01592],[@B28-cancers-12-01592],[@B29-cancers-12-01592],[@B30-cancers-12-01592],[@B31-cancers-12-01592],[@B32-cancers-12-01592],[@B34-cancers-12-01592]\] described the location of lymph node metastases in patients with a squamous cell carcinoma (*n* = 8543). [Table 4](#cancers-12-01592-t004){ref-type="table"} shows the prevalence of lymph node metastases per lymph node station among the seven studies \[[@B22-cancers-12-01592],[@B26-cancers-12-01592],[@B28-cancers-12-01592],[@B29-cancers-12-01592],[@B30-cancers-12-01592],[@B31-cancers-12-01592],[@B34-cancers-12-01592]\] that reported data per lymph node station per tumor location. For patients with an upper thoracic tumor, lymph node metastases are most frequently seen along the right recurrent nerve (60%) and cervical paraesophageal lymph nodes (right 34% and left 22%). For patients with a middle thoracic tumor, the prevalence of lymph node metastases was highest along the right recurrent nerve (23%), right cervical paraesophageal lymph nodes (24%), and middle thoracic paraesophageal lymph nodes (23%). The lymph nodes along the left gastric artery (28%) and lower thoracic esophagus (23%) had the highest prevalence of lymph node metastases in patients with a tumor in the lower thoracic esophagus. Six studies \[[@B24-cancers-12-01592],[@B26-cancers-12-01592],[@B27-cancers-12-01592],[@B28-cancers-12-01592],[@B30-cancers-12-01592],[@B32-cancers-12-01592]\] described the location of the lymph node metastases per region. The results of these studies are shown in [Figure 2](#cancers-12-01592-f002){ref-type="fig"}.

3.3. Distribution Pattern for Esophageal Adenocarcinoma {#sec3dot3-cancers-12-01592}
-------------------------------------------------------

Four studies \[[@B7-cancers-12-01592],[@B23-cancers-12-01592],[@B25-cancers-12-01592],[@B33-cancers-12-01592]\] described the location of lymph node metastases in patients with an adenocarcinoma (*n* = 409). One study \[[@B33-cancers-12-01592]\] described the prevalence of metastatic lymph nodes per lymph node station; this was for GEJ tumors ([Table 4](#cancers-12-01592-t004){ref-type="table"}). Lymph node stations with the highest prevalence of patients with metastatic lymph nodes were lymph nodes along the left gastric artery (48%), lesser curvature (29%), splenic artery (26%), right paracardial lymph nodes (26%), and subcarinal lymph nodes (25%).

Two studies \[[@B23-cancers-12-01592],[@B25-cancers-12-01592]\] described the location of lymph node metastases in regions. Pooled numbers show that for patients with a GEJ tumor, 20% (4 out of 10) had lymph node metastases in the cervical region and 25% (31 out of 124) had metastases in the abdominal lymph node stations (other regions were not reported). For patients with an adenocarcinoma of the lower thoracic esophagus, 35% (6 out of 17) had lymph node metastases in the cervical region, 71% (12 out of 17) had lymph node metastases in the lower mediastinal region, and 71% (12 out of 17) had lymph node metastases in the abdominal region.

One study \[[@B7-cancers-12-01592]\] combined patients with a tumor of the distal esophagus and GEJ. In this study, a prevalence of 30% in the periesophageal lymph nodes, 37% in the paracardial lymph nodes, 35% in the perigastric lymph nodes, and 14% in the celiac axis was reported.

3.4. Distribution of LN Metastases in Relation to pT-Stage {#sec3dot4-cancers-12-01592}
----------------------------------------------------------

Three studies \[[@B24-cancers-12-01592],[@B27-cancers-12-01592],[@B30-cancers-12-01592]\] stratified the prevalence of nodal metastases per pT-stage. All three studies described patients with squamous cell carcinoma. [Table 5](#cancers-12-01592-t005){ref-type="table"} shows the rate of patients with lymph node metastases per region, divided into four groups: patients with pT1-2 and pT3-4 and patients with pT1 and pT2-4. Among patients with higher T-stages, a higher prevalence of lymph node metastases is seen per region, while the distribution remained similar.

4. Discussion {#sec4-cancers-12-01592}
=============

This study describes the sites of lymph node metastases in esophageal cancer patients according to the histology and primary tumor location based on literature published before July 2019. This is the first study systematically combining available evidence on lymph node metastases pattern, contributing toward revealing the lymphatic metastatic pattern of esophageal carcinoma. This study showed that both squamous cell carcinoma and adenocarcinoma metastasize to cervical, thoracic, and abdominal lymph node stations, regardless of the location of the primary tumor.

4.1. Lymphatic Distribution Pattern for Squamous Cell Carcinoma {#sec4dot1-cancers-12-01592}
---------------------------------------------------------------

Multiple studies have attempted to define the lymph node metastases pattern in esophageal cancer \[[@B7-cancers-12-01592],[@B22-cancers-12-01592],[@B23-cancers-12-01592],[@B25-cancers-12-01592],[@B26-cancers-12-01592],[@B27-cancers-12-01592],[@B30-cancers-12-01592],[@B31-cancers-12-01592],[@B32-cancers-12-01592],[@B33-cancers-12-01592]\]. Most of these studies describe squamous cell carcinoma only. The available evidence of lymph node metastases pattern in adenocarcinoma of the esophagus is scarce, and the available literature for both tumor types is very heterogeneous. Whereas some studies report data per lymph node station, others report per region. To make this even more complex, not all studies adhere to the same boundaries of lymph node regions and not all studies use the same anatomical definition of lymph node stations. To define anatomical sites on lymph node stations, some use standardized classification systems such as the AJCC or JES, while others do not use any standardized classification system. Moreover, not all studies report the exact extent of lymphadenectomy. In addition, some studies excluded from this review combined patients with adenocarcinoma and squamous cell carcinoma and/or different tumor locations, which makes data hard to interpret, since these factors could influence the distribution pattern \[[@B35-cancers-12-01592],[@B36-cancers-12-01592],[@B37-cancers-12-01592]\] All together, these factors make comparing available evidence on the lymph node metastases distribution in esophageal cancer difficult.

For upper, middle, as well as lower thoracic esophageal squamous cell carcinoma, the stations around the esophagus are among those with the highest prevalence of lymph node metastases. However, not only lymph node stations in the same region as the tumor have a high prevalence of nodal metastases; stations in different regions are affected as well. For example, 13% of the patients with a lower esophageal tumor have right cervical lymph node metastases.

4.2. Lymphatic Distribution Pattern for Adenocarcinoma {#sec4dot2-cancers-12-01592}
------------------------------------------------------

For adenocarcinoma, although data are more limited, similar results are seen. One-quarter (25%) of patients with a GEJ adenocarcinoma had middle thoracic paraesopahgeal lymph node metastases, and when looking at zones, 20% of the patients with a GEJ adenocarcinoma had lymph node metastases in the cervical zone. An explanation could be the presence of an extensive lymphatic network in the submucosa and even in the lamina propria of the esophagus, with both intramural and longitudinal lymphatic drainage. The longitudinal nature of this network explains the variation in anatomic sites of lymph node metastases \[[@B38-cancers-12-01592],[@B39-cancers-12-01592],[@B40-cancers-12-01592]\]. Another result of the complexity of the lymphatic vessel system is the phenomenon of skip metastases \[[@B37-cancers-12-01592]\]. Skip metastases are distant lymph nodes with metastatic involvement, without tumor infiltration in the regional lymph nodes, and they are more often seen in early tumors \[[@B10-cancers-12-01592]\]. It is unclear what the exact clinical value is since the literature is conflicting on the prognostic relevance \[[@B41-cancers-12-01592],[@B42-cancers-12-01592],[@B43-cancers-12-01592]\].

Three studies \[[@B24-cancers-12-01592],[@B27-cancers-12-01592],[@B30-cancers-12-01592]\] described lymph node metastases per lymph node station in relation to pT-stage in patients with squamous cell carcinoma. An increased prevalence of lymph node metastases is seen per region in patients with a higher pT-stage, while the distribution remained similar. These are small numbers; nevertheless, the literature points out that a higher T-stage is associated with more lymph node metastases \[[@B44-cancers-12-01592]\].

It should be pointed out that this study defines the lymph node metastases pattern based on patients without neoadjuvant treatment because lymph node involvement may differ after neoadjuvant chemo(radio)therapy \[[@B45-cancers-12-01592]\]. Currently, neoadjuvant chemoradiation or perioperative or neoadjuvant chemotherapy is the standard of care in most countries. This makes our results less applicable to current surgical patients, and one of the main questions for the future is whether the lymphadenectomy strategy should be based on the pattern of lymph node metastases before neoadjuvant treatment or after neoadjuvant treatment. However, the location of lymph node metastases in untreated esophageal cancer patients tells us more about the behavior of the disease, and this is fundamental, as this allows for accurately defining neoadjuvant treatment strategies by targeting high-risk regions for lymph node metastases in patients with specific characteristics. A recent study showed that after neoadjuvant chemoradiotherapy, almost half of the patients in that cohort had lymph node metastases outside the radiation field, indicating that the current radiation fields are not sufficient \[[@B46-cancers-12-01592]\]. Although, it should be noted that radiotherapy to an elective nodal area (both metastatic and non-metastatic) does not guarantee a better outcome \[[@B47-cancers-12-01592]\].

There are some limitations of the present study. Firstly, as previously mentioned, studies were very heterogeneous in lymph node dissection and the reporting of anatomical sites of nodal metastases. This heterogeneity might have made our pooled results less reliable. Moreover, not all studies could be pooled per station (since they only described lymph node regions) and vice versa. The inclusion of different studies in [Table 2](#cancers-12-01592-t002){ref-type="table"} and [Table 4](#cancers-12-01592-t004){ref-type="table"} makes displayed percentages slightly different. In addition, few of the studies subdivided patients for T-stage and location of the primary tumor, whilst it has been proven that these factors influence lymph node metastases \[[@B26-cancers-12-01592],[@B48-cancers-12-01592],[@B49-cancers-12-01592]\].

If we want to determine the exact distribution pattern of esophageal cancer, large well-designed prospective studies are needed. One initiative of such a study is the multinational prospective TIGER study (ClinicalTrials.gov Identifier: NCT03222895) \[[@B50-cancers-12-01592]\].

5. Conclusions {#sec5-cancers-12-01592}
==============

Both esophageal squamous cell carcinoma and adenocarcinoma are aggressive diseases that can metastasize to cervical, thoracic, as well as abdominal lymph node stations, regardless of the location of the primary tumor. The prevalence of patients with metastatic lymph nodes per station and region could be determined for squamous cell carcinoma. However, few studies described the distribution of lymph node metastases for esophageal adenocarcinoma, and the data for both tumor types was very heterogeneous. This complicates evidence-based treatment strategies in both neoadjuvant (radiation field) and surgical (lymphadenectomy) treatment. Well-designed prospective studies are needed to determine the exact lymphatic distribution pattern of esophageal cancer.
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cancers-12-01592-t0A1_Table A1

###### 

Search strategy for PubMed (22 July 2019).

  Search   Query                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Items Found
  -------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------
  \#1      ((((((((((("Esophageal Neoplasms"\[Mesh\] OR "Esophagectomy"\[Mesh\] OR ((esophagus\[tiab\] OR esophageal\[tiab\] OR esophagogastric\[tiab\] OR oesophagus\[tiab\] OR oesophageal\[tiab\] OR oesophagogastric\[tiab\] OR gastroesophag\*\[tiab\] OR gastrooesophag\*\[tiab\]) AND (neoplas\*\[tiab\] OR cancer\*\[tiab\] OR carcino\*\[tiab\] OR adenocarcino\*\[tiab\] OR tumor\[tiab\] OR tumors\[tiab\] OR tumour\[tiab\] OR tumours\[tiab\] OR malig\*\[tiab\])) OR esophagectom\*\[tiab\])) AND ("Lymph Nodes"\[Mesh\] OR "Lymphatic Metastasis"\[Mesh\] OR ((lymph\[tiab\] OR lymphatic\[tiab\]) AND (node\*\[tiab\] OR nodal\[tiab\] OR metastas\*\[tiab\])))))) AND (("Neoplasm Staging"\[Mesh\] OR staging\[tiab\] OR TNM\[tiab\] OR number\[tiab\] OR extent\[tiab\] OR extended\[tiab\] OR scoring\[tiab\] OR score\[tiab\] OR classif\*\[tiab\] OR categor\*\[tiab\] OR criteria\[tiab\] OR 2-field\*\[tiab\] OR two-field\*\[tiab\] OR 3-field\*\[tiab\] OR three-field\*\[tiab\] OR node status\[tiab\] OR nodal status\[tiab\] OR D1\[tiab\] OR D2\[tiab\] OR N0\[tiab\] OR N1\[tiab\] OR N2\[tiab\] OR N3\[tiab\] OR pattern\*\[tiab\] OR drainage\[tiab\] OR spread\[tiab\] OR pathway\*\[tiab\] OR depth\[tiab\])))) NOT ((express\*\[ti\] OR overexpress\*\[ti\] OR gene\[ti\] OR genes\[ti\] OR protein\*\[ti\] OR p53\[ti\] OR serum\[ti\] OR (case\[ti\] AND report\[ti\]))) NOT (Animals\[Mesh\] NOT Humans\[Mesh\])) AND (english\[la\] OR dutch\[la\]))))   4106

\[Mesh\] = Medical subject headings; \[tiab\] = words in title OR abstract; \[ti\] = words in title; \[la\] = language.

cancers-12-01592-t0A2_Table A2

###### 

Search strategy for Embase.com (22 July 2019).

  \#   Searches                                                                                                                                                                                                                                                                                                                                                                                                                                                   Results
  ---- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------
  1    exp esophagus tumor/or esophagus resection/or esophagectom\*.ti,ab,kw. or ((esophagus or esophageal or esophagogastric or oesophagus or oesophageal or oesophagogastric or gastroesophag\* or gastrooesophag\*) and (neoplas\* or cancer\* or carcino\* or adenocarcino\* or tumor or tumors or tumour or tumours or malig\*)).ti,ab,kw.                                                                                                                   127708
  2    (exp lymph node/or exp lymph node metastasis/or ((lymph or lymphatic) and (node\* or nodal or metastas\*)).ti,ab,kw.) and (cancer staging/or (staging or TNM or number or extent or extended or scoring or score or classif\* or categor\* or criteria or 2-field\* or two-field\* or 3-field\* or three-field\* or node status or nodal status or D1 or D2 or N0 or N1 or N2 or N3 or pattern\* or drainage or spread or pathway\* or depth).ti,ab,kw.)   208651
  3    1 and 2                                                                                                                                                                                                                                                                                                                                                                                                                                                    10765
  4    (express\* or overexpress\* or gene or genes or protein\* or p53 or serum or (case and report)).ti.                                                                                                                                                                                                                                                                                                                                                        2592018
  5    animal/ not human/                                                                                                                                                                                                                                                                                                                                                                                                                                         1423187
  6    conference abstract.pt. or conference paper/ or letter/                                                                                                                                                                                                                                                                                                                                                                                                    4893909
  7    3 not 4 not 5 not 6                                                                                                                                                                                                                                                                                                                                                                                                                                        6444
  8    limit 7 to (dutch or english)                                                                                                                                                                                                                                                                                                                                                                                                                              5195

exp = EMtree keyword with explosion; de = EMtree keyword without explosion; .ab,ti,kw = words in title OR abstract OR keyword; .ti = words in title; .pt = publication type.

![Flow-chart of study selection. \* Three studies by Chen and colleagues and two by Li and colleagues described (partly) the same cohort of patients. Therefore, only one study of Chen et al. and one study of Li et al. were included. For both, this was the study where most of the lymph node stations and/or regions were described.](cancers-12-01592-g001){#cancers-12-01592-f001}

![Prevalence of lymph node metastases per tumor location in patients with squamous cell carcinoma. (**A**) = Upper thoracic esophageal tumor, (**B**) = Middle thoracic esophageal tumor, (**C**) = Distal thoracic esophageal tumor. Data presented as percentage of patients with lymph node metastases in this region.](cancers-12-01592-g002){#cancers-12-01592-f002}

cancers-12-01592-t001_Table 1

###### 

Combination of JES and AJCC stations and five lymph node regions.

  Node Region                     Station Number (JES)                          Name of Station (JES)                       Station Number (AJCC)                                                                                                                           Name of Node Station (AJCC)
  ------------------------------- --------------------------------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------
  Cervical                        104R                                          Right supraclavicular lymph nodes                                                                                                                                                           
  104L                            Left supraclavicular lymph nodes                                                                                                                                                                                                          
  101R                            Right cervical paraesophageal lymph nodes     1R                                          Right lower cervical paratracheal lymph nodes                                                                                                   
  101L                            Left cervical paraesophageal lymph nodes      1L                                          Left lower cervical paratracheal lymph nodes                                                                                                    
  102                             Deep cervical lymph nodes                                                                                                                                                                                                                 
  103                             Peripharyngeal lymph nodes                                                                                                                                                                                                                
  Upper mediastinal               105                                           Upper thoracic paraesophageal lymph nodes   8up                                                                                                                                             Posterior mediastinal lymph nodes
  106preR                         Right pretracheal lymph nodes                                                                                                                                                                                                             
  106preL                         Left pretracheal lymph nodes                                                                                                                                                                                                              
  106recR                         Right recurrent nerve lymph nodes             2R                                          Right and left upper paratracheal nodes (including lymph nodes along the recurrent laryngeal nerve and the cervical paratracheal lymph nodes)   
  106recL                         Left recurrent nerve lymph nodes              2L + 4L                                     Left upper paratracheal nodes + Left lower paratrachal lymph nodes                                                                              
  106tbR                          Right tracheobronchial lymph nodes                                                        Right lower paratrachal lymph nodes                                                                                                             
  106tbL                          Left tracheobronchial lymph nodes             4L                                          Left lower paratrachal lymph nodes                                                                                                              
  Middle mediastinal              107                                           Subcarinal lymph nodes                      7                                                                                                                                               Subcarinal lymph nodes
  108                             Middle thoracic paraesophageal lymph nodes    8M                                          Middle thoracic paraesophageal lymph nodes                                                                                                      
  109R                            Right main bronchus lymph nodes               7                                           Subcarinal lymph nodes                                                                                                                          
  109L                            Left main bronchus lymph nodes                7                                           Subcarinal lymph nodes                                                                                                                          
  Lower mediastinal               110                                           Lower thoracic paraesophageal lymph nodes   8Lo                                                                                                                                             Lower thoracic paraesophageal lymph nodes
  111                             Supradiaphragmatic lymph nodes                15                                          Diaphragmatic lymph nodes                                                                                                                       
  112                             Posterior mediastinal lymph nodes             9                                           Pulmonary ligament lymph nodes                                                                                                                  
  Abdominal lymph node stations   1                                             Right paracardial lymph nodes               16                                                                                                                                              Paracardial lymph nodes
  2                               Left paracardial lymph nodes                  16                                          Paracardial lymph nodes                                                                                                                         
  3                               Lesser curvature lymph nodes                  17                                          Lymph nodes along the left gastric artery                                                                                                       
  4                               Lymph nodes along the greater curvature                                                                                                                                                                                                   
  7                               Lymph nodes along the left gastric artery     17                                          Lymph nodes along the left gastric artery                                                                                                       
  9                               Celiac lymph nodes                            20                                          Celiac lymph nodes                                                                                                                              
  8                               Lymph nodes along the common hepatic artery   18                                          Lymph nodes along the common hepatic artery                                                                                                     
  11                              Splenic artery lymph nodes                    19                                          Splenic artery lymph nodes                                                                                                                      
  19                              Infradiaphragmatic lymph nodes                16                                          Paracardial lymph nodes                                                                                                                         

JES = Japan Esophageal Society; AJCC = American Joint Committee on Cancer; Lymph node stations 5, 6, 10, and 12 to 20 of the JES classification not described in this review.

cancers-12-01592-t002_Table 2

###### 

Characteristics of included studies.

  No   First Author                                Year of Publication   Study Design                      Country          Number of Patients   Inclusion Period   2- or 3-Field Lymphadenectomy   Lymph Node Classification System Used   Use of Immunohistochemistry Staining   MINORS Score   How Detailed Are the Locations of Lymph Node Metastases Described?                                                                                          How Are the Locations of Nodal Metastases Reported?
  ---- ------------------------------------------- --------------------- --------------------------------- ---------------- -------------------- ------------------ ------------------------------- --------------------------------------- -------------------------------------- -------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------
  1    S. Sharma \[[@B22-cancers-12-01592]\]       1994                  Retrospective study               Japan            70                   1985--1991         3-field                         No standard classification used         NR                                     10             Description of several stations in cervical, thoracic, and abdominal regions.                                                                               Number of patients with resected and positive lymph nodes reported per station.
  2    C. van de Ven \[[@B23-cancers-12-01592]\]   1999                  Prospective observational study   Belgium          37                   1994--1998         3-field                         No standard classification used         NR                                     11             Description of several stations in cervical, thoracic, and abdominal regions.                                                                               Number of patients with resected and positive lymph nodes reported per region.
  3    H. Igaki \[[@B24-cancers-12-01592]\]        2001                  Retrospective study               Japan            96                   1986--1998         3-field                         No standard classification used         NR                                     8              No description of stations. Cervical, upper mediastinal, middle mediastinal, lower mediastinal, perigastric, and celiac regions described.                  Number of patients with resected and positive lymph nodes reported per region. Numbers per station were not provided.
  4    S.M. Dresner \[[@B25-cancers-12-01592]\]    2001                  Retrospective study               United Kingdom   104                  1996--1999         2-field                         No standard classification used         NR                                     10             Description of stations in lower thoracic and abdominal regions.                                                                                            Number of patients with resected and positive lymph nodes reported for the abdominal region. Numbers per station were not provided.
  5    J. Chen \[[@B26-cancers-12-01592]\]         2009                  Retrospective study               China            1850                 1993--2006         3-field                         JES                                     H&E                                    12             Description of stations according to JES in cervical, upper mediational, middle mediastinal, lower mediastinal and abdominal region.                        Number of patients with resected and positive lymph nodes reported per region and station.
  6    Y. Tachimori \[[@B27-cancers-12-01592]\]    2011                  Retrospective study               Japan            356                  2001--2005         3-field                         No standard classification used         NR                                     10             No description of stations. Cervical, upper mediastinal, middle mediastinal, lower mediastinal, perigastric and celiac regions described.                   Number of patients with resected and positive lymph nodes reported per region. Numbers per station were not provided.
  7    C. Castoro \[[@B7-cancers-12-01592]\]       2011                  Retrospective study               Italy            248                  1992--2007         2-field and 3-field             No standard classification used         H&E and PAS                            11             Description of stations in cervical, thoracic and abdominal regions.                                                                                        Number of patients with resected and positive lymph nodes reported per station.\*
  8    H. Li \[[@B28-cancers-12-01592]\]           2012                  Retrospective study               China            200                  2000--2010         3-field                         No standard classification used         H&E                                    11             No description of stations. Cervical, mediastinal, recurrent laryngeal nerve and abdominal regions described.                                               Number of patients with resected and positive lymph nodes reported per region and the recurrent laryngeal nerve station.
  9    S. Kosugi \[[@B29-cancers-12-01592]\]       2013                  Retrospective study               Japan            86                   1992--2011         3-field                         JES                                     NR                                     11             Description of stations according to JES in cervical, upper mediational, middle mediastinal, lower mediastinal, perigastric, and suprapancreatic regions.   Number of patients with resected and positive lymph nodes reported per station.
  10   J. Cheng \[[@B30-cancers-12-01592]\]        2013                  Retrospective study               China            1893                 2003--2011         2-field and 3-field             JES                                     H&E                                    9              Description of stations according to JES in cervical, upper mediational, middle mediastinal, lower mediastinal, and abdominal region.                       Number of patients with resected and positive lymph nodes reported per region and per a selected number of stations.
  11   Z. Lin \[[@B31-cancers-12-01592]\]          2016                  Prospective observational study   China            260                  2009--2013         3-field                         AJCC                                    H&E                                    13             Description of stations according to AJCC in the thoracic and abdominal region.                                                                             Number of patients with resected and positive lymph nodes reported per station.
  12   Y. Dong \[[@B32-cancers-12-01592]\]         2015                  Retrospective study               China            3587                 2000--2014         2-field and 3-field             JES                                     NR                                     10             Description of stations according to JES in the cervical, upper mediastinal, middle mediastinal, lower mediastinal, and abdominal regions.                  Number of patients with resected and positive lymph nodes reported per region. Numbers per station were not provided.\*
  13   X. Duan \[[@B33-cancers-12-01592]\]         2017                  Retrospective study               China            136                  2014--2016         2-field and 3-field             No standard classification used         NR                                     11             Description of stations in thoracic and abdominal regions.                                                                                                  Number of patients with resected and positive lymph nodes reported per station.
  14   S. Park \[[@B34-cancers-12-01592]\]         2018                  Prospective observational study   Korea            29                   2014--2018         3-field                         JES                                     H&E                                    10             Description of stations according to JES in the cervical, upper mediastinal, middle mediastinal, lower mediastinal, and abdominal regions.                  Number of patients with resected and positive lymph nodes reported per station.

Studies are shown in chronological order; JES = Japan Esophageal Society; AJCC = American Joint Committee on Cancer; \* Partly combined locations of the tumor in displayed data; H&E = hematoxylin & eosin; PAS = periodic acid-Schiff; NR = not reported; MINORS score ranges from 0 to 16 for non-comparative studies with 16 being the ideal score.
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###### 

Study population characteristics.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No   First Author                                Sex, Male *n* (%)   Age, in years              Histology       T-Stage \*, *n* (%)   N-Stage \*, *n* (%)   Location of the Tumor, *n* (%)   Surgical Approach           Number of Dissected Lymph Nodes per Patient   Percentage of Patients with Lymph Node Metastases   Overall Percentage of Positive Lymph Nodes
  ---- ------------------------------------------- ------------------- -------------------------- --------------- --------------------- --------------------- -------------------------------- --------------------------- --------------------------------------------- --------------------------------------------------- --------------------------------------------
  1    S. Sharma \[[@B22-cancers-12-01592]\]       62 (89)             mean 58.5                  SCC             pT1 11 (16)\          pN0 20 (29)\          UTE 10 (14)\                     Open procedures             mean 82                                       71%\                                                4%\
                                                                                                                  pT2 12 (17)\          pN1 50 (71)           MTE 37 (53)\                                                                                               (50/70)                                             (208/5720)
                                                                                                                  pT3 46 (65)\                                LTE 23 (33)                                                                                                                                                    
                                                                                                                  pT5 1 (2)                                                                                                                                                                                                  

  2    C. van de Ven \[[@B23-cancers-12-01592]\]   NR                  NR                         AC              cT3                   NR                    LTE 17 (46)\                     Open procedures             mean 60,\                                     NR                                                  14%\
                                                                                                                                                              GEJ 20 (54)                                                  SD 17                                                                                             (323/2240)

  3    H. Igaki \[[@B24-cancers-12-01592]\]        85 (97)             mean 62\                   SCC             pT1 27 (28)\          pN0 36 (38)\          LTE                              Open procedures             NR                                            66%\                                                NR
                                                                       \[range 42--86\]                           pT2 16 (16)\          pN1 60 (62)                                                                                                                      (63/96)                                             
                                                                                                                  pT3 53 (56)                                                                                                                                                                                                

  4    S.M. Dresner \[[@B25-cancers-12-01592]\]    91 (88)             mean 63\                   AC              NR                    NR                    GEJ                              Open procedures             median 22\                                    70% (73/104)                                        21%\
                                                                       \[range 30--78\]                                                                                                                                    \[range 11--57\]                                                                                  (508/2476)

  5    J. Chen \[[@B26-cancers-12-01592]\]         1351 (73)           median 55\                 SCC             cT1 109 (6)\          NR                    UTE 289 (16)\                    Open procedures             mean 26\                                      58%\                                                9%\
                                                                       \[range 27--54\]                           cT2 348 (19)\                               MTE 1381 (74)\                                               \[range 15--71\]                              (1081/1850)                                         (4350/47470)
                                                                                                                  cT3 1215 (65)\                              LTE 180 (10)                                                                                                                                                   
                                                                                                                  cT4 178 (10)                                                                                                                                                                                               

  6    Y. Tachimori \[[@B27-cancers-12-01592]\]    314 (88)            mean 63\                   SCC             pT1 127 (36)\         pN0 110 (31)\         UTE 55 (15)\                     Open procedures             NR                                            NR                                                  NR
                                                                       \[range 41--80\]                           pT2 40 (11)\          pN1 116 (33)\         MTE 173 (49)\                                                                                                                                                  
                                                                                                                  pT3 183 (51)\         pN2 81 (23)\          LTE 128 (36)                                                                                                                                                   
                                                                                                                  pT4 6 (2)             pN3 49 (13)                                                                                                                                                                          

  6    C. Castoro \[[@B7-cancers-12-01592]\]       327 (81)            median 63 \[IQR 56--70\]   SCC 116 (47)\   cT1 5 (2)\            cN0 107 (43)\         UTE (all SCC) 25 (10)\           Open procedures             AC median 19.5\                               AC 54%\                                             NR
                                                                                                  AC 132 (53)     cT2 42 (17)\          cN1 141 (57)          MTE (all SCC) 50 (20)\                                       \[IQR 15--27\]\                               (63/116)\                                           
                                                                                                                  cT3 201 (81)                                LTE (AC 15, SCC 41) 56 (23)\                                 SCC median 16\                                SCC 67%\                                            
                                                                                                                                                              GEJ (all AC) 117 (47)                                        \[IQR 12--21\]                                (88/132)                                            

  8    H. Li \[[@B28-cancers-12-01592]\]           163 (82)            mean 57,\                  SCC             pT1 18 (9)\           NR                    UTE 31 (15)\                     Open procedures             NR                                            NR                                                  NR
                                                                       SD 9                                       pT2 45 (23)\                                MTE 137 (69)\                                                                                                                                                  
                                                                                                                  pT3 114 (56)\                               LTE 32 (16)                                                                                                                                                    
                                                                                                                  pT4 23 (12)                                                                                                                                                                                                

  9    S. Kosugi \[[@B29-cancers-12-01592]\]       78 (91)             mean 60,\                  SCC             pT1a 7 (8)\           pN0 48 (56)\          UTE 17 (20)\                     Open procedures             NR                                            47%\                                                NR
                                                                       SD 7                                       pT1b 75 (87)\         pN1 31 (36)\          MTE 59 (69)\                                                                                               (40/86)                                             
                                                                                                                  pT2 4 (5)             pN2 6 (7)\            LTE 10 (11)                                                                                                                                                    
                                                                                                                                        pN3 1 (1)                                                                                                                                                                            

  10   J. Cheng \[[@B30-cancers-12-01592]\]        1474 (78)           \< 40: 1%\                 SCC             cTis 10 (1)\          NR                    UTE 82 (4)\                      Open procedures             mean 13                                       46%\                                                NR
                                                                       41--59: 48%\                               cT1 103 (5)\                                MTE 1266 (67)\                                                                                             (865/1893)                                          
                                                                       ≥60: 51%                                   cT2 345 (18)\                               LTE 545 (29)                                                                                                                                                   
                                                                                                                  cT4 1173 (62)\                                                                                                                                                                                             
                                                                                                                  cT4 262 (14)                                                                                                                                                                                               

  11   Z. Lin \[[@B31-cancers-12-01592]\]          59 (23)             median 61\                 SCC             pT1 30 (11)\          pN0 119 (46)\         UTE 28 (11)\                     Open procedures             median 35\                                    54%\                                                15%\
                                                                       \[IQR 52--67\]                             pT2 44 (17)\          pN1 67 (25)\          MTE 173 (67)\                                                \[IQR 25--46\]                                (141/260)                                           (316/2097)
                                                                                                                  pT3 164 (63)\         pN2 54 (21)\          LTE 59 (22)                                                                                                                                                    
                                                                                                                  pT4 22 (9)            pN3 20 (8)                                                                                                                                                                           

  12   Y. Dong \[[@B32-cancers-12-01592]\]         2536 (72)           median 61                  SCC             pT1 435 (14)\         pN0 2223 (62)\        UTE 189 (5)\                     Hybrid procedures           mean 20\                                      38%\                                                4%\
                                                                                                                  pT2 935 (25)\         pN1 1233 (34)\        MTE 1837 (51)\                                               \[range 16--50\]                              (1.364/3587)                                        (2870/71740)
                                                                                                                  pT3 1992 (55)\        pN2 98 (3)\           LTE 1561 (44)                                                                                                                                                  
                                                                                                                  pT4 225 (6)           pN3 33 (1)                                                                                                                                                                           

  13   X. Duan \[[@B33-cancers-12-01592]\]         128 (95)            mean 63,\                  AC              pT1-2 17 (13)\        pN0 44 (32)\          GEJ                              Open procedures             mean 15                                       68%\                                                21%\
                                                                       SD 9                                       pT3-4 119 (87)        pN1 64 (47)\                                                                                                                     (92/136)                                            (431/2083)
                                                                                                                                        pN2 21 (15)\                                                                                                                                                                         
                                                                                                                                        pN3 7 (6)                                                                                                                                                                            

  14   S. Park \[[@B34-cancers-12-01592]\]         26 (90)             mean 63,\                  SCC             cT1                   cN0 25 (86)\          MTE 17 (59)\                     Robot-assisted procedures   mean 55,\                                     86%\                                                NR
                                                                       SD 7                                                             cN1 4 (14)            LTE 12 (41)                                                  SD 17                                         (25/29)                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Studies are shown in chronological order; SCC = squamous cell carcinoma; AC = adenocarcinoma; GEJ = gastroesophageal junction; CE = Cervical esophagus; UTE = Upper thoracic esophagus; MTE = middle thoracic esophagus; LTE = lower thoracic esophagus; NR = not reported; SD = standard deviation; IQR = interquartile range; \* either pathological or clinical T and N-stage, based on what is reported in the paper.
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###### 

Prevalence of lymph node metastases per lymph node station.

  Lymph Node Station                            Squamous Cell Carcinoma   Adenocarcinoma                                                                          
  --------------------------------------------- ------------------------- ---------------- --- ----- ------ ----- --- ------ ----- ----- --- ----- ----- ---- --- -----
  **Cervical region**                                                                                                                                             
  Right supraclavicular lymph nodes             9%                        34               /   381   10%    266   /   2684   13%   100   /   748   NR             
  Left supraclavicular lymph nodes              5%                        14               /   299   5%     67    /   1418   3%    6     /   203   NR             
  Right cervical paraesophageal lymph nodes     34%                       103              /   299   24%    345   /   1418   10%   20    /   203   NR             
  Left cervical paraesophageal lymph nodes      22%                       65               /   299   11%    152   /   1418   4%    8     /   203   NR             
  Right deep cervical lymph nodes               2%                        5                /   289   \<1%   4     /   1381   0%    0     /   180   NR             
  Left deep cervical lymph nodes                2%                        5                /   289   1%     8     /   1381   0%    0     /   180   NR             
  Peripharyngeal lymph nodes                    1%                        2                /   289   \<1%   1     /   1381   0%    0     /   180   NR             
  **Upper mediastinal region**                                                                                                                                    
  Upper thoracic paraesophageal lymph nodes     10%                       40               /   388   6%     163   /   2811   3%    7     /   214   NR             
  Right pretracheal lymph nodes                 12%                       43               /   371   6%     81    /   1381   2%    3     /   180   NR             
  Left pretracheal lymph nodes                  9%                        28               /   299   7%     101   /   1418   2%    4     /   203   NR             
  Right recurrent nerve lymph nodes             60%                       6                /   10    23%    15    /   66     15%   8     /   52    NR             
  Left recurrent nerve lymph nodes              11%                       32               /   289   7%     102   /   1410   3%    7     /   209   NR             
  Tracheobronchial lymph nodes                  12%                       10               /   82    12%    17    /   145    6%    3     /   49    NR             
  **Middle mediastinal region**                                                                                                                                   
  Subcarinal lymph nodes                        8%                        32               /   398   18%    517   /   2913   14%   121   /   836   25%   1    /   4
  Middle thoracic paraesophageal lymph nodes    5%                        20               /   388   23%    595   /   2542   21%   170   /   804   2%    1    /   45
  Right main bronchus lymph nodes               \<1%                      1                /   289   2%     24    /   1410   2%    4     /   209   0%    0    /   10
  Left main bronchus lymph nodes                1%                        2                /   289   3%     37    /   1410   2%    5     /   209   6%    2    /   31
  **Lower mediastinal region**                                                                                                                                    
  Lower thoracic paraesophageal lymph nodes     3%                        12               /   388   8%     221   /   2851   23%   184   /   809   10%   10   /   96
  Supradiaphragmatic lymph nodes                0%                        0                /   306   \<1%   3     /   1504   5%    39    /   778   0%    0    /   5
  Posterior mediastinal lymph nodes             3%                        10               /   316   7%     102   /   1545   5%    14    /   259   0%    0    /   17
  **Abdominal region**                                                                                                                                            
  Right paracardial lymph nodes                 1%                        2                /   199   3%     48    /   1447   12%   27    /   232   26%   33   /   128
  Left paracardial lymph nodes                  3%                        10               /   299   7%     201   /   2684   13%   97    /   748   37%   48   /   131
  Lesser curvature lymph nodes                  3%                        9                /   299   10%    273   /   2713   11%   89    /   777   29%   37   /   127
  Lymph nodes along the greater curvature       0%                        0                /   289   \<1%   1     /   1381   0%    0     /   180   12%   5    /   41
  Lymph nodes along the left gastric artery     4%                        11               /   299   16%    238   /   1528   28%   76    /   269   48%   29   /   60
  Celiac lymph nodes                            NR                                                   2%     1     /   56     3%    1     /   33    14%   4    /   29
  Lymph nodes along the common hepatic artery   \<1%                      1                /   289   3%     40    /   1483   5%    37    /   774   14%   5    /   37
  Splenic artery lymph nodes                    NR                                                   2%     1     /   59     0%    0     /   31    26%   11   /   43
  Infradiaphragmatic lymph nodes                NR                                                   NR                      NR                    NR             
  Subaortic lymph nodes                         NR                                                   10%    2     /   21     0%    0     /   6     NR             
  Para-aortic lymph nodes                       NR                                                   10%    1     /   10     0%    0     /   3     NR             

NR = not reported. Data presented as percentage of patients with lymph node metastases with number of patients with (number of patients with metastatic lymph nodes/number of patients with lymph node dissection of this station). Only studies that presented data per lymph node station were included in this table.
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###### 

Lymph node metastases per pathological T-stage of patients with esophageal carcinoma.

  Lymph Node Region           MTE   LTE   UTE   MTE   LTE                           
  --------------------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  Cervical region             3%    5%    2%    3%    14%   21%   12%   25%   0%    6%
  Upper mediastinal region    3%    6%    2%    5%    55%   85%   22%   61%   13%   27%
  Middle mediastinal region   18%   38%   9%    19%   5%    9%    6%    49%   5%    23%
  Lower mediastinal region    2%    3%    27%   39%   0%    9%    9%    25%   5%    27%
  Abdominal region            11%   16%   25%   33%   NR    NR    NR    NR    NR    NR
  Perigastric region          NR    NR    NR    NR    0%    6%    24%   54%   39%   66%
  Celiac region               NR    NR    NR    NR    0%    9%    3%    5%    0%    9%

Data presented as percentage of patients with lymph node metastases in this region. UTE = Upper thoracic esophagus; MTE = Middle thoracic esophagus; LTE = Lower thoracic esophagus; NR = not reported.
